YWYoshitaka Watanabe

Yoshitaka Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshitaka Watanabe has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to Letter to the Editor on “Association Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study”

    by Shota Endo, Hirokazu Ikeda, Yuma Iwanaka, Takahiro Ono, Chisato Oyake, Yuta Onuki, Yoshitaka Watanabe, Masaki Fuyama, Tsuneki Watanabe

  • Open Access

    Association Between Toilet Training Timing and Prognosis of Nocturnal Enuresis in Children: A Retrospective Study

    by Shota Endo, Hirokazu Ikeda, Yuma Iwanaka, Takahiro Ono, Chisato Oyake, Yuta Onuki, Yoshitaka Watanabe, Masaki Fuyama, Tsuneki Watanabe

    Aims: Toilet training (TT) is a critical developmental milestone with potential implications for lower urinary tract function. However, its association with the prognosis of nocturnal enuresis (NE) remains unclear. We aimed to evaluate whether the timing of TT initiation and completion affects 1‐year treatment outcomes in children with NE. Methods: We conducted a retrospective cohort study of 163 children diagnosed with NE between April 2020 and March 2023. Patients were classified into complete response (CR) and non‐CR groups based on 1‐year treatment outcomes. Data on TT timing, constipation, and daytime incontinence (DI) were obtained from medical records and a structured questionnaire. Statistical analyses included the chi‐square test, Mann–Whitney U test, and multivariate logistic regression. Results: The median age of the cohort was 8 years, and 66.9% of the patients were male. TT was initiated before 3 years of age in 67.5% of patients and completed before 4 years of age in 50.9%. Early TT completion was associated with a significantly lower rate of DI; however, no significant association was observed between TT timing and achievement of CR. In multivariate analysis, neither early TT initiation nor early TT completion independently predicted CR. Conclusions: Although early TT may be associated with a reduced prevalence of DI, TT timing was not significantly associated with CR at 1 year in this cohort. Constipation and DI were associated with lower odds of CR in the exploratory multivariable analysis.


  • Open Access

    Association between sodium content of intravenous immunoglobulin and electrolyte changes and clinical course of Kawasaki disease

    by Yoshitaka Watanabe, Naomi Yagi, Toya Hattori, Chisato Oyake, Shota Endo, Maria Yoshimi, Takayoshi Kyoda, Hirokazu Ikeda

    Background: Intravenous immunoglobulin (IVIG) formulations used to treat Kawasaki disease differ markedly in sodium content; however, the clinical significance of this factor remains unclear.Purpose: Here we investigated whether sodium content influences electrolyte changes and short-term clinical outcomes of Kawasaki disease.Methods: This single-center retrospective cohort study included 744 children with first-episode Kawasaki disease treated with 2-kg IVIG in 2010–2020. The patients were categorized into high-sodium (Glovenin-I or Venilon-I) and low-sodium (Venoglobulin IH) groups. Serum electrolytes, total protein, and immunoglobulin G levels were measured before and after IVIG administration. Outcomes included additional IVIG administration and the presence of coronary artery lesions.Results: Compared to the low-sodium group, the high-sodium group had significantly increased serum sodium (2.9±3.2 mEq/L vs. 1.7±2.7 mEq/L) but significantly decreased serum potassium (-0.13±0.50 mEq/L vs. -0.03±0.49 mEq/L) levels after IVIG therapy. After its administration, hyponatremia occurred more often in the low-sodium group (4.4% vs. 0.3%), whereas hypokalemia occurred more frequently in the high-sodium group (9.9% vs. 5.5%). Total protein, immunoglobulin G, and albumin levels were higher in the low-sodium group. The rates of additional IVIG use and coronary artery lesions did not differ significantly between groups.Conclusion: Our findings demonstrate that the sodium content of IVIG contributes to distinct changes in electrolyte and protein concentrations during the acute phase of Kawasaki disease. However, these biochemical differences were not associated with short-term clinical outcomes. Awareness of formulation-specific profiles may help clinicians interpret laboratory findings appropriately during IVIG therapy.

  • A Rare Case of Kawasaki Disease Complicating Poststreptococcal Acute Glomerulonephritis

    by Yuki Ihara, Yoshitaka Watanabe, Sakura Motegi, Takashi Iwaku, Tsuneki Watanabe, Hirokazu Ikeda

  • Open Access

    Kawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine

    by Yasuyuki Sahara, Naomi Yagi, Yoshitaka Watanabe, Koichiro Aoki, Takashi Iwaku, Makiko Tominaga, Hirokazu Ikeda

    Background: Kawasaki disease is a systemic inflammatory disorder that is frequently encountered in routine pediatric clinical practice. Conversely, trisomy 18 is a chromosomal disorder with a historically poor prognosis. However, recent advances in medical care have improved its survival, with a reported 1‐year survival rate reaching 29%. Despite this improvement, studies describing the clinical course of individuals with trisomy 18 beyond the first year of life remain scarce. Moreover, to our knowledge, cases of Kawasaki disease with trisomy 18 have not been reported. Case Presentation: We report a case of a 3‐year‐11‐month‐old girl with trisomy 18 who presented with persistent fever and rash and, subsequently, fulfilled five of the six principal diagnostic criteria for Kawasaki disease. Because intravenous immunoglobulin resistance was predicted based on the Kobayashi score, initial treatment consisted of intravenous immunoglobulin (2 g/kg), aspirin, and oral cyclosporine concurrent with current Japanese guidelines. Defervescence was achieved without complications, and no adverse events were observed during treatment. No coronary artery abnormalities were observed during the acute phase or at 1‐, 3‐, and 6‐month follow‐up evaluations. Discussion: We present a case of trisomy 18 treated according to Japanese guidelines for Kawasaki disease. Treatment regimen, which included cyclosporine, was safely administered, and the patient experienced a favorable clinical course. To improve the life expectancy of this patient group, it is crucial to accumulate comprehensive natural history, including the efficacy of standard treatments for various pediatric conditions. This will enable timely and appropriate therapeutic interventions.

  • Open Access

    Safety and efficacy of vibegron in pediatric patients with treatment-resistant nocturnal enuresis: a multicenter retrospective study

    by Hirokazu Ikeda, Yoshitaka Watanabe, Yoshiyuki Ohtomo, Hiroki Miyano, Shuichiro Fujinaga, Yusuke Gonda, Atsuko Hata, Shoji Tsuji, Yoshiyuki Shiroyanagi, Naoto Nishizaki, et al.

    Background: Nocturnal enuresis (NE) is a common chronic condition in children. Although enuresis alarms and desmopressin are the first-line treatments recommended by clinical guidelines, 20–40% of affected children demonstrate inadequate response and require additional therapeutic interventions. β3-adrenoceptor agonists are emerging as promising alternatives to anticholinergics, offering a more favorable safety profile with a lower incidence of common side effects. This multicenter retrospective study aimed to evaluate the safety and effectiveness of vibegron in children with treatment-resistant NE (TR-NE) and compare different treatment strategies. Methods: This retrospective observational study was conducted at 12 hospitals affiliated with the Japanese Society on Enuresis and Incontinence. It enrolled children aged 5–18 years who received vibegron (50 mg once daily) for refractory NE between November 2018 and December 2021. The median treatment duration was 245 (interquartile range, 126–484) days. The primary outcome was treatment efficacy, assessed by the change in the number of wet nights over 30 days from baseline to 1 month. Safety was evaluated by monitoring adverse events. Treatment response was defined using the International Children’s Continence Society criteria. Patients were classified into an “add-on” group (vibegron combined with existing therapy) or a “switch” group (transitioned from prior anticholinergics to vibegron). Results: Of the 387 children enrolled, 386 were included for safety analysis and 369 for efficacy evaluation. Four patients (1.0%) experienced mild adverse events that led to the discontinuation of vibegron, and all resolved promptly. Overall, 52.8% achieved a partial or complete response (CR) (≥50% reduction in wet nights), and 17.3% achieved a CR. The add-on group showed significantly greater improvements than the switch group (56.9% vs. 40.1% reduction, Pvs. 11%, P=0.006). Among the subgroups, the alarm addition subgroup showed the greatest reduction in wet nights (71.6%), while triple therapy also achieved high efficacy (61.6%). Conclusions: Vibegron is a safe and effective option for pediatric patients with TR-NE. Add-on strategies—particularly triple therapy—were more effective than monotherapy switching, strengthening the incorporation of vibegron as part of multimodal treatment strategies. Given the retrospective nature of the study, prospective randomized trials are warranted to confirm these findings and optimize the treatment protocols.


  • Open Access

    Late-onset afebrile neonatal bacteremia due to nontypeable Haemophilus influenzae: A case report

    by Wataru Anzai, Yoshitaka Watanabe, Naomi Yagi, Masaki Yamaguchi, Nobuhiro Kawai, Hirokazu Ikeda

  • Open Access

    Arthritis associated with Kawasaki disease after initial combination therapy with cyclosporine: a case report

    by Kaori Yoshida, Yoshitaka Watanabe, Maria Yoshimi, Nobuhiro Kawai, Minako Matsumoto, Hirokazu Ikeda

    Background: Since the 2020 revision of the Kawasaki disease (KD) treatment guidelines, there have been few reports of reactive arthritis secondary to treatment-resistant KD. This study reports a case of KD that required initial treatment with cyclosporine A (CyA) followed by additional infliximab (IFX) and secondary to reactive arthritis. Case Description: A 5-year-old boy met diagnostic criteria for KD on day 5 of fever and had an intravenous immunoglobulin (IVIG) refractory predictive score of 8 (≥5) was administered ulinastatin, IFX, and three IVIG doses in combination with CyA. His fever resolved on day 9. Subsequently, acetylsalicylic acid was changed to flurbiprofen and then to dipyridamole due to suspicion of a drug rash. Fever and pain appeared in ankle joints and right hip joint on day 18 of illness. Prednisolone (PSL) was started on day 23 of illness for reactive arthritis associated with KD, which improved the joint pain. No recurrence of joint symptoms or coronary artery lesions was observed after tapering off of PSL. Conclusions: Based on the evaluation at the start of treatment, although CyA is initially administered in potential IVIG-resistant patients, attention must be paid to secondary reactive arthritis if the patient becomes resistant to treatment and requires IFX treatment.

  • Factors influencing the efficacy and self‐discontinuation of alarm therapy for Japanese patients with nocturnal enuresis

    by Masaki Fuyama, Hirokazu Ikeda, Yuma Iwanaka, Takahiro Ono, Chisato Oyake, Shota Endo, Yuta Onuki, Yoshitaka Watanabe, Tsuneki Watanabe

    Background: Alarm therapy is the recommended first‐line treatment for nocturnal enuresis (NE). This study aimed to investigate the effectiveness of alarm monotherapy, identify predictors of treatment success, and examine factors contributing to self‐discontinuation in Japanese patients with NE. Methods: We retrospectively analyzed the treatment course of 112 patients with NE who received alarm monotherapy between January 2017 and September 2024. The primary outcome was the predictors of treatment effectiveness, and the secondary outcome was factors contributing to self‐discontinuation of alarm therapy. Results: At 3 months after initiating alarm monotherapy, treatment was effective in 49 patients (≥50% reduction in NE), while 41 showed poor response (p = 0.006), developmental disabilities ( p = 0.004), no prior NE treatment ( p = 0.011), and ineffective treatment at 3 and 6 months ( p = 0.001 and 0.045, respectively). Conclusions: Alarm monotherapy can be recommended for any patient as no factors predicting effectiveness were identified. However, patients with no prior treatment, DUI, neurodevelopmental disorders, or ineffective alarm therapy may struggle to continue treatment with alarm monotherapy.

  • Open Access

    Renoprotective effects of coenzyme Q10 supplementation in patients with chronic kidney disease: a protocol for a systematic review

    by Yoshifusa Abe, Hiroki Nishiwaki, Taihei Suzuki, Hisashi Noma, Yoshitaka Watanabe, Erika Ota, Takeshi Hasegawa

    Introduction Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-like quinone. The plasma levels of CoQ10 are reduced in patients with chronic kidney disease (CKD). CoQ10 supplementation can improve mitochondrial function and decrease oxidative stress in these patients. This systematic review will assess the renoprotective effects of CoQ10 supplementation in patients with CKD. Methods and analysis We will include the following studies: (1) randomised-controlled trials, (2) participants with CKD and (3) participants treated with CoQ10 as an intervention. The systematic review protocol was prepared in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and International Clinical Trials Register databases will be searched for articles without language restrictions in December 2024. The authors will be divided into two groups. Two independent authors will screen the titles and abstracts of all reports extracted via an electronic search. After the initial screening, the authors will independently review the full-text articles and perform a directed content analysis of the extracted data. For outcomes measured using continuous scales of measurement, we will adopt standardised mean differences as the effect measures. We will pool the data using the random‐effects model. Ethics and dissemination No human participants will be involved in the study. On completion of the analysis, the manuscript will be prepared for publication in a peer-reviewed journal. PROSPERO registration number CRD42021241085.